Sante Health Ventures — Full Portfolio
6 tracked investments · listed companies and verified rows first
BiotechCleveland, US
Kevin Lalande(Director)Howard Dittrich(Executive Officer)Robert Baltera, Jr.(Executive Officer, Director)Jerel Davis(Director)James Topper(Director)
Board seatKevin Lalande· per SEC Form D · $31.9M raise · filed Feb 2015
Austin, US
Board seatJoe CunninghamKevin Lalande· per SEC Form D · $30M raise · filed Oct 2022
HealthtechAustin, US
Kevin Lalande(Director)Lew Little(Director)Michael Gonzales(Executive Officer, Director)Evan Melrose(Director)Barry Fromberg(Executive Officer, Director)
Board seatKevin Lalande· per SEC Form D · $8.4M raise · filed Apr 2015
BiotechAustin, US
Kevin M. Lalande(Director)Richard John Hawkins(Executive Officer, Director)George Gilbert Cloyd(Director)Robert Heft(Director)Jon S. Saxe(Director)Edward J. Mathers(Director)
Board seatKevin M. Lalande· per SEC Form D · $13M raise · filed May 2015
BiotechAustin, US
Jason S. Kim(Executive Officer)Eric E. Poma(Executive Officer, Director)David R. Hoffmann(Director)Michael Broxson(Director)David Hirsch(Director)David Valacer(Executive Officer)
Board seatKevin LalandeKevin M. Lalande· per SEC Form D · $90.7M raise · filed Jul 2023
Sensorium Therapeutics is a clinical-stage biotech company developing novel CNS therapies for anxiety, epilepsy, and cognitive dysfunction using its SensAI platform, which integrates AI, chemistry, and curated natural product data to identify therapeutic patterns from over 50 million biological relationships.
AI & Machine LearningBiotechDigital HealthMedford, US
Jerrold Rosenbaum(Director)inJacob Hooker(Executive Officer, Director)inPranav Tadi(Executive Officer)
BoardRyan Katz(Director)inRichard Simon(Director)
Board seatKevin Lalande· per SEC Form D · $58.5M raise · filed Jul 2025
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.